|Bid||218.44 x 10000|
|Ask||218.57 x 3400|
|Day's range||217.67 - 220.38|
|52-week range||176.13 - 238.52|
|Beta (5Y monthly)||0.35|
|PE ratio (TTM)||N/A|
|Earnings date||19 Feb 2021|
|Forward dividend & yield||1.15 (0.52%)|
|Ex-dividend date||25 Mar 2021|
|1y target est||184.40|
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, announces the U.S. Food and Drug Administration (FDA) clearance of the new Cochlear™ Baha® 6 Max Sound Processor, designed to improve hearing outcomes for people with SSD (single-sided deafness), conductive or mixed hearing loss.
Cochlear has joined people with hearing loss, hearing care experts and advocates in welcoming the World Health Organization's (WHO) landmark World Report on Hearing, which calls upon governments and societies to prioritize hearing health.